Areas of Expertise
  • Biopharma
  • Life Science Tools & Instrumentation
  • Genomics
  • SaaS
  • Public Companies
  • Mergers & Acquisitions
  • Venture Funding
Contact Linda Rubinstein
Download vCard
Recent Blog Posts
CEO Advice: How to Select the RIGHT Interim CFO
Read More
Fundraising Choices in Life Sciences: What, When & Why?
Read More

All Posts

Linda Rubinstein

Linda Rubinstein joined FLG in 2010 and has also served on the firm’s Management Committee.

Linda has over 30 years of operational, financial and capital markets experience in life sciences, SaaS and investment banking and has been CFO of numerous public and private companies.  She has built particular expertise in the life sciences sector, notably in biotechnology, life science tools, genomics and diagnostics.  While at FLG, Linda has served as the permanent or interim CFO of Adverum, Apexigen, ArmaGen, Five Prime, Ingenuity, iPierian, Kezar, Medikine, PaxVax, Retrotope, Sublimity, True North and Tunitas, among others.  As CFO, Linda has overseen finance at R&D and commercial-stage enterprises, led and executed public and private financing and M&A transactions, contributed to operations and strategy, and acted as a trusted business partner to CEOs and executive teams.  Over the course of her career, Linda has raised more than $5 billion in private and public market financings and as CFO has generated more than $1 billion in realized value from M&A transactions.

Prior to FLG, as an investment banker, Linda completed over 30 transactions, raising capital for companies ranging from emerging start-ups to Fortune 500 companies. Linda was also the sole principal of RDJ Advisors, providing interim CFO and other consulting services to life science and SaaS companies. Previously, as the CFO of Solexa, a publicly traded firm manufacturing and selling genetic analysis instrumentation, consumables and services, Linda was responsible for raising over $100 million in PIPE financings and negotiating the sale of Solexa to Illumina, Inc. in a $600 million stock-for-stock transaction announced in November 2006.  Earlier, Linda served as Vice President of Finance at ChemoCentryx, a biotechnology company, and as Senior Vice President of Lehman Brothers’ Global Healthcare Investment Banking Group. Linda serves on the board of Biocept, a molecular diagnostics company, was formerly a board member of Sensorin, an analytical instrument company, and of non-profits JVS and Impact Bay Area.

Linda earned B.A. and M.A. degrees in Economics (summa cum laude and Phi Beta Kappa) from the University of California, Los Angeles.

Linda's Perspective on FLG

FLG allows me to better serve my clients in two ways.  I have a couple dozen partners who are available to help me serve my client better, with their referrals, introductions, experience and technical expertise.  And when I’m fully committed and can’t take on a new client, often one or more of my partners has the right skill set, experience and expertise to step in.

- Linda Rubinstein

Sector Experience
  • Technology
  • Life Sciences
  • SaaS - Technology
  • Diagnostics
  • Biopharma
  • Medtech
  • Healthcare IT
Selected Engagements
RenovoRx Biopharma Public
Kezar Life Sciences Biopharma Interim CFO Private
PaxVax Biopharma Permanent CFO
EpiBiome, Inc. Biopharma Interim CFO Private
Retrotope, Inc. Biopharma Interim CFO Private
ArmaGen, Inc. Biopharma Interim CFO Private
Tunitas Therapeutics, Inc. Biopharma Interim CFO Private
True North Therapeutics Life Sciences Permanent CFO Private
iPerian, Inc. Biopharma Interim CFO Private
Ingenuity Systems, Inc. Healthcare Services Permanent CFO Private
Past Directorships
Impact Bay Area
Videos Featuring Linda Rubinstein
Creative Strategic and Financing Solutions for Life Sciences Companies
CFO Priorities: From the IPO Organizational Meeting to Preparing the S-1
IPO Preparation: Additional IPO Workstreams Before You File Your S-1

View All Videos